MIR5192: A Potential Drug Target and Biomarker for the Treatment of Obesity

Target Name: MIR5192

NCBI ID: G100847087

MIR5192

Other Name(s): hsa-miR-5192 | hsa-mir-5192 | MicroRNA 5192 | microRNA 5192

MIR5192: A Potential Drug Target and Biomarker for the Treatment of Obesity

Obesity has become a significant public health issue in recent years, with over 20% of adults in the United States obesity. This increasing prevalence has led to a range of chronic diseases, including diabetes, cardiovascular disease, and certain types of cancer. In addition, obesity has also been associated with significant mental health issues, such as depression and anxiety.

MIR5192 is a potential drug target and biomarker that may be used to treat obesity. It is a small intercalated RNA molecule that has been shown to have a negative impact on the expression of genes involved in obesity development and metabolism.

The obese mouse phenotype is a well-established model for obesity research, and has been used to study the underlying molecular mechanisms that contribute to human obesity. MIR5192 has been shown to be involved in the regulation of obesity-related genes, including those involved in metabolism, inflammation, and insulin sensitivity.

In addition to its potential therapeutic applications, MIR5192 has also been shown to be a potential biomarker for obesity. The obese mouse phenotype has been used to identify genes that are differentially expressed in obese compared to lean mice, and MIR5192 has been shown to be one of these genes.

Furthermore, MIR5192 has also been shown to be involved in the regulation of energy metabolism, which is a key aspect of obesity. Obesity is often associated with decreased energy expenditure and increased energy intake, leading to an energy imbalance that contributes to weight gain. MIR5192 has been shown to be involved in the regulation of energy metabolism by promoting the expression of genes involved in lipid metabolism and energy expenditure.

In conclusion, MIR5192 is a potential drug target and biomarker for the treatment of obesity. Its negative impact on the expression of genes involved in obesity development and metabolism, as well as its involvement in energy metabolism, make it a promising candidate for obesity treatment. Further research is needed to fully understand the potential clinical applications of MIR5192, as well as to develop safe and effective treatments for obesity.

Protein Name: MicroRNA 5192

The "MIR5192 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR5192 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets